Last reviewed · How we verify
Hyperbaric Bupivacaine HCl 0.5%
At a glance
| Generic name | Hyperbaric Bupivacaine HCl 0.5% |
|---|---|
| Sponsor | Sintetica SA |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Intrathecal Nalbuphine Versus Intrathecal Tramadol as Adjuvants in Subarachnoid Block for Lower Limb Orthopaedic Surgeries (NA)
- Intrathecal Bupivacaine With or Without Dexmetomidine for Cesserian Delivery (PHASE2)
- Bupivacaine for Postoperative Pain After Laparoscopic Hysterectomy (NA)
- The Effect of Epidural Anesthesia on Optic Nerve Sheath Diameter Measurements in Total Knee Prosthesis Surgery (NA)
- Pericapsular Nerve Group Block Versus Intrathecal Morphine for Analgesia After Total Hip Arthroplasty (NA)
- Maternal Satisfaction After Spinal Anesthesia for Cesarean Delivery
- Comparing Doses of Intrathecal Dexmedetomidine (PHASE4)
- Intrathecal MoRphine Versus Transabdominal Plane Block (TAP) Block for AnalGesic Management in Elective Caesarean Section (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hyperbaric Bupivacaine HCl 0.5% CI brief — competitive landscape report
- Hyperbaric Bupivacaine HCl 0.5% updates RSS · CI watch RSS
- Sintetica SA portfolio CI